5 Key Takeaways

• 1

  Early resolution of retinal fluid after starting faricimab therapy predicts longer treatment intervals in neovascular age-related macular degeneration patients.

• 2

  Participants achieving intraretinal fluid and subretinal fluid resolution within 12 weeks had nearly double the odds of extended dosing intervals.

• 3

  At week 112, patients with early fluid resolution were more likely to remain on longer dosing intervals and had better visual outcomes.

• 4

  Faricimab's dual mechanism of inhibiting Ang-2 and VEGF-A may enhance rapid anatomical effects and treatment durability.

• 5

  Identifying early predictors of treatment durability could help tailor strategies and reduce the injection burden for nAMD patients.